Pancreatic Cancer Trial, Recruiting NCT07080021 Sponsor: Ruijin Hospital Condition: Pancreatic Cancer
Back to Pancreatic Cancer

Pancreatic Cancer Trial, Recruiting

NCT07080021
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are between 18 and 75 years old (any gender).
  • You have been diagnosed with pancreatic cancer confirmed by a tissue sample (biopsy), and your cancer falls into one of three categories: high-risk but potentially removable by surgery, borderline removable by surgery, or locally advanced (not yet spread to distant parts of the body).
  • Your cancer has been reviewed by a team of specialists who agree that treatment before surgery (neoadjuvant therapy) is appropriate for you.
  • You are generally well enough to carry out light activity and care for yourself (a standard health score of 0 or 1 on a common medical scale).
  • Your doctors estimate you are likely to live at least 6 months.
  • Your heart, liver, and kidneys are working well enough, based on recent blood tests showing liver and kidney values within an acceptable range.
  • You are willing and able to sign a consent form agreeing to take part.

Who may not be able to join:

  • Your cancer has already spread to distant parts of your body (such as other organs).
  • You have previously had any cancer treatment, including chemotherapy, radiation, immunotherapy, targeted therapy, or certain traditional Chinese medicine anti-cancer treatments.
  • You currently have another active cancer.
  • You are pregnant or breastfeeding.
  • You have had a serious allergic reaction to any of the drugs used in the standard treatment plan for this type of cancer.
  • You have previously had a stem cell transplant or an organ transplant.
  • You have a condition that weakens your immune system, including HIV infection, active Hepatitis B, active Hepatitis C, or a combination of these infections (confirm with trial site for full details on immune conditions).

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: +86 021-64370045-678805

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Registry
ClinicalTrials.gov
Start date
20 May 2025
Est. completion
20 May 2026

Where this trial is recruiting

🇨🇳 China

Primary endpoints

The correlation between ctDNA-MRD status at serial monitoring points during neoadjuvant therapy and therapeutic efficacy (R0 resection).

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov